Document is current
Any future updates will be listed below
-
Authors
Reghuvaran, Anand https://orcid.org/0000-0002-5656-0205
Kumar, Ashwani https://orcid.org/0000-0002-0086-7398
Lin, Qisheng
Rajeevan, Nallakandi https://orcid.org/0000-0002-2045-0872
Banu, Khadija
Sun, Zeguo
Shi, Hongmei
Barsotti, Gabriel
Tanvir, EM
Pell, John
Perincheri, Sudhir
Wei, Chengguo https://orcid.org/0000-0002-7940-8310
Bharathan, Bhavya
Planoutene, Marina
Eichmann, Anne
Mas, Valeria
Zhang, Weijia https://orcid.org/0009-0005-0151-4200
Cantley, Lloyd G. https://orcid.org/0000-0002-8444-6469
Xu, Leyuan https://orcid.org/0000-0002-3071-9206
Das, Bhaskar
He, John Cijiang https://orcid.org/0000-0002-1502-2849
Menon, Madhav C. https://orcid.org/0000-0002-9567-4299
- License Information
-
More Information
Article History
Received: 13 February 2025
Accepted: 10 December 2025
First Online: 30 December 2025
Competing interests
: L.G.C. declares roles as advisor to Pfizer for AKI and CKD and to Dropshot for AKI. The remaining authors declare no competing interests.
